What diseases does Pralsetinib treat?

Pralsetinib (Pralsetinib) is a targeted therapy drug used to treat a specific type of cancer, namely cancer associated with RET gene rearrangements. These cancers include thyroid cancer, non-small cell lung cancer, colorectal cancer and other rare cancer types. Platinib helps control the progression of the disease by inhibiting the activity of RET kinase, blocking the growth and spread of cancer cells. Platinib is only available with a doctor's prescription and only under professional supervision.

Platinib is approved based on the percentage of patients whose tumors shrink or disappear after treatment and how long this response lasts. It is used to treat certain cancers caused by abnormal rearrangements of the (RET) gene during transfection, such as adult patients with non-small cell lung cancer (NSCLC) that have spread, patients with Adults and children 12 years and older who have advanced medullary thyroid cancer (MTC) or MTC that has spread and require oral or injectable medications (systemic therapy); adults and children 12 years and older who have advanced thyroid cancer or thyroid cancer that has spread and require oral or injectable medications (systemic therapy) who have received radioactive iodine therapy but it did not work or is no longer effective.

It is understood that the original drug Platinib has been launched in China, but it has not yet entered the scope of medical insurance. The price of each box of 100mg*120 tablets may be around 60,000 yuan, which is expensive. The price of the European version of 100mg*60 capsules sold overseas may be around 40,000 yuan per box, and the price of the American version may be around 150,000 yuan per box (prices may fluctuate due to exchange rates). The ingredients of domestic and foreign original drugs are basically the same. There is currently no generic version of Platinib available on the market. Please consult your medical consultant for specific prices and drug details.